JPWO2019224711A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019224711A5 JPWO2019224711A5 JP2020564908A JP2020564908A JPWO2019224711A5 JP WO2019224711 A5 JPWO2019224711 A5 JP WO2019224711A5 JP 2020564908 A JP2020564908 A JP 2020564908A JP 2020564908 A JP2020564908 A JP 2020564908A JP WO2019224711 A5 JPWO2019224711 A5 JP WO2019224711A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- polypeptide sequence
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims description 256
- 239000000427 antigen Substances 0.000 claims description 82
- 102000038129 antigens Human genes 0.000 claims description 82
- 108091007172 antigens Proteins 0.000 claims description 82
- 102000004965 antibodies Human genes 0.000 claims description 50
- 108090001123 antibodies Proteins 0.000 claims description 50
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 35
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 210000004027 cells Anatomy 0.000 claims description 20
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 102100016493 CD33 Human genes 0.000 claims description 11
- 101700017647 CD33 Proteins 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 201000005787 hematologic cancer Diseases 0.000 claims description 10
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 8
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 8
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 8
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims description 8
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims description 4
- 102000002110 C2 domain Human genes 0.000 claims description 4
- 108050009459 C2 domain Proteins 0.000 claims description 4
- 210000004443 Dendritic Cells Anatomy 0.000 claims description 4
- 206010024324 Leukaemias Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010025310 Other lymphomas Diseases 0.000 claims description 4
- 210000002381 Plasma Anatomy 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 201000009251 multiple myeloma Diseases 0.000 claims description 4
- 108010071919 Bispecific Antibodies Proteins 0.000 claims description 2
- 230000036947 Dissociation constant Effects 0.000 claims description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N Fucose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 2
- 201000009030 carcinoma Diseases 0.000 claims description 2
- 230000003013 cytotoxicity Effects 0.000 claims description 2
- 231100000135 cytotoxicity Toxicity 0.000 claims description 2
- 230000001419 dependent Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000002489 hematologic Effects 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims 4
- 206010058314 Dysplasia Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862676123P | 2018-05-24 | 2018-05-24 | |
| US62/676,123 | 2018-05-24 | ||
| US201962825846P | 2019-03-29 | 2019-03-29 | |
| US62/825,846 | 2019-03-29 | ||
| PCT/IB2019/054182 WO2019224711A2 (en) | 2018-05-24 | 2019-05-21 | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021524244A JP2021524244A (ja) | 2021-09-13 |
| JPWO2019224711A5 true JPWO2019224711A5 (ru) | 2022-05-25 |
Family
ID=67211770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564908A Pending JP2021524244A (ja) | 2018-05-24 | 2019-05-21 | 抗ｃｄ３３抗体、抗ｃｄ３３／抗ｃｄ３二重特異性抗体、及びその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11466082B2 (ru) |
| EP (1) | EP3802606A2 (ru) |
| JP (1) | JP2021524244A (ru) |
| KR (1) | KR20210013156A (ru) |
| CN (1) | CN112189022A (ru) |
| AU (1) | AU2019274229A1 (ru) |
| BR (1) | BR112020023357A2 (ru) |
| CA (1) | CA3101270A1 (ru) |
| CL (1) | CL2020003028A1 (ru) |
| CO (1) | CO2020014575A2 (ru) |
| CR (1) | CR20200567A (ru) |
| EC (1) | ECSP20075198A (ru) |
| IL (1) | IL278844A (ru) |
| JO (1) | JOP20190116A1 (ru) |
| MA (1) | MA52771A (ru) |
| MX (1) | MX2020012588A (ru) |
| NI (1) | NI202000088A (ru) |
| PE (1) | PE20210180A1 (ru) |
| PH (1) | PH12020552010A1 (ru) |
| SG (1) | SG11202011210TA (ru) |
| TW (1) | TW202033551A (ru) |
| UY (1) | UY38242A (ru) |
| WO (1) | WO2019224711A2 (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018516248A (ja) | 2015-05-29 | 2018-06-21 | アンフィヴェナ セラピューティクス，インク． | 二重特異性のｃｄ３３およびｃｄ３結合タンパク質を使用する方法 |
| SG11202011270QA (en) | 2018-05-24 | 2020-12-30 | Janssen Biotech Inc | Anti-cd3 antibodies and uses thereof |
| DE102018127845A1 (de) | 2018-11-07 | 2020-05-07 | Grimme Landmaschinenfabrik Gmbh & Co. Kg | Verfahren zur Regelung des Betriebs einer Maschine zum Ernten von Hackfrüchten |
| MX2021009975A (es) * | 2019-02-22 | 2021-12-10 | Memorial Sloan Kettering Cancer Center | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer. |
| KR20220123410A (ko) * | 2019-12-09 | 2022-09-06 | 트위스트 바이오사이언스 코포레이션 | 아데노신 수용체를 위한 변이체 핵산 라이브러리 |
| IL302349A (en) * | 2020-03-13 | 2023-06-01 | Janssen Biotech Inc | Materials and methods for binding SIGLEC-3/CD33 |
| US20210284731A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
| WO2021202726A2 (en) * | 2020-03-31 | 2021-10-07 | Fred Hutchinson Cancer Research Center | Anti-cd33 antibodies and uses thereof |
| US11919944B2 (en) | 2020-05-11 | 2024-03-05 | Augmenta Biosciences, Inc. | Antibodies for SARS-CoV-2 and uses thereof |
| AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
| WO2022159620A1 (en) * | 2021-01-21 | 2022-07-28 | Twist Bioscience Corporation | Methods and compositions relating to adenosine receptors |
| BR112023016121A2 (pt) | 2021-02-16 | 2023-11-28 | Janssen Pharmaceutica Nv | Anticorpo triespecífico que direciona bcma, gprc5d e cd3 |
| CA3214594A1 (en) | 2021-03-24 | 2022-09-29 | Janssen Biotech, Inc. | Trispecific antibody targeting cd79b, cd20, and cd3 |
| CN115443333A (zh) * | 2021-04-27 | 2022-12-06 | 上海驯鹿生物技术有限公司 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
| EP4377354A1 (en) * | 2021-07-30 | 2024-06-05 | Nanjing Legend Biotech Co., Ltd. | Anti-cd33 antibodies and uses thereof |
| CN118234750A (zh) * | 2021-09-02 | 2024-06-21 | 纪念斯隆-凯特琳癌症中心 | 抗cd33抗体和其用途 |
| WO2023037333A1 (en) * | 2021-09-13 | 2023-03-16 | Janssen Biotech, Inc | CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER |
| WO2023081898A1 (en) * | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| EA010570B1 (ru) | 2002-11-07 | 2008-10-30 | Иммьюноджен, Инк. | Антитело к cd33 и способы его применения |
| AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| CN101687915B8 (zh) | 2007-04-03 | 2018-08-03 | 安进研发（慕尼黑）股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
| BRPI0809594A2 (pt) | 2007-04-03 | 2019-08-27 | Micromet Ag | polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s) |
| MX2009010611A (es) | 2007-04-03 | 2010-03-26 | Micromet Ag | Enlazadores biespecificos, especificos para especies. |
| BRPI0919841A2 (pt) | 2008-10-01 | 2014-11-18 | Micromet Ag | Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas |
| DK2352763T4 (da) | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
| EP2352765B1 (en) | 2008-10-01 | 2018-01-03 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| MX353144B (es) | 2010-04-20 | 2017-12-20 | Genmab As | Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas. |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| PT2773671T (pt) | 2011-11-04 | 2021-12-14 | Zymeworks Inc | Geração de anticorpo heterodimérico estável com mutações no domínio fc |
| PT3653049T (pt) | 2012-12-14 | 2023-11-14 | Omniab Inc | Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem |
| AR097648A1 (es) * | 2013-09-13 | 2016-04-06 | Amgen Inc | Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide |
| KR20160098328A (ko) | 2013-12-13 | 2016-08-18 | 제넨테크, 인크. | 항-cd33 항체 및 면역접합체 |
| US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| CA2959171C (en) * | 2014-09-05 | 2023-11-14 | Janssen Pharmaceutica Nv | Cd123 binding agents and uses thereof |
| US11136390B2 (en) | 2015-06-12 | 2021-10-05 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| WO2016201389A2 (en) * | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| BR112019023789A2 (pt) | 2017-08-03 | 2020-07-28 | Alector Llc | anticorpos anti-cd33 e métodos de uso dos mesmos |
| JP2021514206A (ja) | 2018-02-20 | 2021-06-10 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３を標的とする抗体可変ドメイン及びその使用 |
| SG11202011270QA (en) * | 2018-05-24 | 2020-12-30 | Janssen Biotech Inc | Anti-cd3 antibodies and uses thereof |
-
2018
- 2018-05-24 JO JOP/2019/0116A patent/JOP20190116A1/ar unknown
-
2019
- 2019-05-21 EP EP19737216.2A patent/EP3802606A2/en active Pending
- 2019-05-21 AU AU2019274229A patent/AU2019274229A1/en active Pending
- 2019-05-21 BR BR112020023357-9A patent/BR112020023357A2/pt unknown
- 2019-05-21 PE PE2020001885A patent/PE20210180A1/es unknown
- 2019-05-21 JP JP2020564908A patent/JP2021524244A/ja active Pending
- 2019-05-21 CR CR20200567A patent/CR20200567A/es unknown
- 2019-05-21 CA CA3101270A patent/CA3101270A1/en active Pending
- 2019-05-21 US US16/418,420 patent/US11466082B2/en active Active
- 2019-05-21 KR KR1020207036865A patent/KR20210013156A/ko unknown
- 2019-05-21 SG SG11202011210TA patent/SG11202011210TA/en unknown
- 2019-05-21 MX MX2020012588A patent/MX2020012588A/es unknown
- 2019-05-21 CN CN201980034952.6A patent/CN112189022A/zh active Pending
- 2019-05-21 MA MA052771A patent/MA52771A/fr unknown
- 2019-05-21 WO PCT/IB2019/054182 patent/WO2019224711A2/en unknown
- 2019-05-23 TW TW108117806A patent/TW202033551A/zh unknown
- 2019-05-24 UY UY0001038242A patent/UY38242A/es unknown
-
2020
- 2020-11-19 IL IL278844A patent/IL278844A/en unknown
- 2020-11-20 CL CL2020003028A patent/CL2020003028A1/es unknown
- 2020-11-23 EC ECSENADI202075198A patent/ECSP20075198A/es unknown
- 2020-11-23 PH PH12020552010A patent/PH12020552010A1/en unknown
- 2020-11-23 NI NI202000088A patent/NI202000088A/es unknown
- 2020-11-24 CO CONC2020/0014575A patent/CO2020014575A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019224711A5 (ru) | ||
| CN111944050B (zh) | 一种抗b7-h3抗体及其应用 | |
| JP2018534933A5 (ru) | ||
| JP2019146572A5 (ru) | ||
| JPWO2019173420A5 (ru) | ||
| BR112019016204A2 (pt) | anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d | |
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2019532056A5 (ru) | ||
| JP2019536740A5 (ru) | ||
| JP2020529863A (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| JP2017529838A5 (ru) | ||
| JP2013534809A5 (ru) | ||
| JP2017510559A5 (ru) | ||
| RU2014113304A (ru) | Анти-cd40-антитела, применение и методы | |
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| RU2012103212A (ru) | Tlr3 связывающие агенты | |
| JP2012532851A5 (ru) | ||
| CN114502591B (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| JPWO2019173291A5 (ru) | ||
| JP2020522280A5 (ru) | ||
| JP2020522281A5 (ru) | ||
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| JP2017521054A5 (ru) | ||
| JPWO2019224717A5 (ru) | ||
| JP2020515277A5 (ru) |